| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Gilman Steven C is a Director at Akebia Therapeutics, Inc. with holdings across 3 companies. Recent SEC Form 4 filings include 0 buys and 10 sells.
Estimated insider holdings value: $634K based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 16, 2024 | VCEL Vericel Corp | Director | Sale+OE | 5,833 | $41.36 | $241,252.88 | -34.7% | +42.2% | -15.8% | |
| Oct 2, 2024 | VCEL Vericel Corp | Director | Sale+OE | 5,833 | $40.35 | $235,361.55 | -34.7% | +34.9% | -22.6% | |
| Sep 18, 2024 | VCEL Vericel Corp | Director | Sale+OE | 5,834 | $45.54 | $265,680.36 | -34.7% | +22.3% | -31.3% | |
| Sep 4, 2024 | VCEL Vericel Corp | Director | Sale+OE | 5,000 | $48.58 | $242,900.00 | -31.3% | +21.4% | -29.8% | |
| Jun 3, 2022 | AKBA Akebia Therapeutics, Inc. | Director | Sell | 4,567 | $0.36 | $1,653.25 | -9.5% | -9.7% | +168.3% | |
| Apr 29, 2022 | VCEL Vericel Corp | Director | Sell | 900 | $30.94 | $27,846.00 | -14.8% | +10.9% | +10.6% | |
| Nov 29, 2021 | VCEL Vericel Corp | Director | Sale+OE | 5,000 | $39.17 | $195,855.00 | -58.8% | +10.5% | -43.2% | |
| Oct 27, 2021 | VCEL Vericel Corp | Director | Sale+OE | 5,000 | $50.57 | $252,870.00 | -58.8% | -33.6% | -49.0% | |
| Sep 30, 2021 | VCEL Vericel Corp | Director | Sale+OE | 5,000 | $48.85 | $244,255.00 | -58.8% | -16.1% | -52.5% | |
| Jun 7, 2021 | AKBA Akebia Therapeutics, Inc. | Director | Sell | 4,567 | $3.32 | $15,163.35 | -8.7% | -13.4% | -87.5% |